Aoruite Pharmaceutical

Aurisco Pharmaceutical, also known as Aoruite Pharmaceutical, is a leading Chinese pharmaceutical company focused on the development and manufacture of complex Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Established in 1998 and headquartered in Zhejiang, the company has built a global reputation as a specialist in steroid hormones and respiratory medications. In recent years, Aurisco has strategically expanded its technological capabilities to include advanced platforms for peptides and oligonucleotides, positioning itself as a key player in the GLP-1 and RNA therapeutics markets. The company operates as a comprehensive CDMO, offering end-to-end services from process development to commercial-scale production across multiple GMP-certified facilities. Aurisco is publicly traded on the Shanghai Stock Exchange and serves a diverse international clientele, including major global pharmaceutical firms. Its commitment to green chemistry and high-quality standards has made it a preferred partner for high-potency and complex molecule manufacturing.